A Phase II Study of Anecortave Acetate for the Treatment of Exudative Age-Related Macular Degeneration

Phase 2

Completed

• Conditions: AMD
• Interventions: Drug: Anecortave Acetate 15 mg; Drug: Anecortave acetate 30 mg; Drug: Anecortave Acetate 3 mg; Other: Anecortave Acetate Vehicle

• Registration Number: NCT00346957
• Lead Sponsor: Alcon Research

Brief Summary

The purpose of the study is to determine the concentration of anecortave acetate (15 or 30 mg versus placebo) that is safe and effective for the inhibition of the growth of blood vessels in the retina in patients with wet AMD.

Detailed Description

Not available

Study Timeline

• Study Start: 1999-04
• Primary Completion: 2003-04
• Study Completion: 2003-04
• Study First Submitted: 2006-06-28
• Study First Submitted QC: 2006-06-30
• Study First Posted: 2006-07-04
• Status Verified: 2012-03
• Last Update Submitted: 2012-03-03
• Last Update Posted: 2012-03-06

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 128

Inclusion Criteria

• Ages 50 years and over
• Other protocol-defined inclusion and exclusion criteria may apply.

Exclusion Criteria

Not provided

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Anecortave Acetate 15	Anecortave Acetate 15 mg	-
Anecortave Acetate 30	Anecortave acetate 30 mg	-
Anecortave Acetate 3	Anecortave Acetate 3 mg	-
Anecortave Acetate Vehicle	Anecortave Acetate Vehicle	-

Primary Outcome Measures

Name	Time	Method
Mean change in logMAR visual acuity at 12 months from baseline.	12 months